(NASDAQ: IONS) Ionis Pharmaceuticals's forecast annual revenue growth rate of 26.25% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.96%, and while it is forecast to beat the US market's average forecast revenue growth rate of 13.56%.
Ionis Pharmaceuticals's revenue in 2026 is $943,711,000.On average, 25 Wall Street analysts forecast IONS's revenue for 2026 to be $139,461,703,367, with the lowest IONS revenue forecast at $129,644,342,153, and the highest IONS revenue forecast at $157,859,137,632. On average, 22 Wall Street analysts forecast IONS's revenue for 2027 to be $229,947,279,312, with the lowest IONS revenue forecast at $160,239,554,510, and the highest IONS revenue forecast at $285,782,179,030.
In 2028, IONS is forecast to generate $311,882,516,768 in revenue, with the lowest revenue forecast at $218,053,454,520 and the highest revenue forecast at $411,328,107,390.